SUN-LB064 A Phase 2, Dose-Escalation, Safety and Efficacy Study of Tildacerfont (SPR001) for the Treatment of Patients with Classic Congenital Adrenal Hyperplasia
2015 ◽
Vol 100
(3)
◽
pp. 1137-1145
◽
2007 ◽
Vol 92
(3)
◽
pp. 1015-1018
◽